[Combination chemotherapy of CDDP and etoposide in advanced non-small cell carcinoma of the lung].
Twenty-seven patients with advanced and previously untreated non-small cell carcinoma of the lung received combination chemotherapy with CDDP (100 mg/m2 iv on day 1) and etoposide (100 mg/m2 iv on day 2, 4 and 6). Eleven partial responses were observed (response rate of 40.7%), and the median survival of patients was 44.4 weeks. Toxicity was tolerable with moderate myelosuppression. This combination chemotherapy should be recommended for further clinical trials.
Kodama
N
N
National Kinki Chuo Hospital, Sakai.
Furuse
K
K
Kawahara
M
M
Arai
R
R
Yamamoto
M
M
Tsuruta
M
M
Kubota
K
K
Ogawara
M
M
Nakai
R
R
Kawano
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged
D005047:Etoposide; D002945:Cisplatin